The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)
Official Title: A Pilot Trial of OSI-461 in Patients With Chronic Lymphocytic Leukemia
Study ID: NCT00073489
Brief Summary: The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL patients.
Detailed Description: The primary objective of this study is to determine the activity of OSI-461 given twice daily orally in previously untreated CLL patients. The secondary objective is to evaluate the safety profile of OSI-461 in this patient population.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Arizona Hematology & Oncology Associates, Phoenix, Arizona, United States
Rocky Mountain Cancer Centers, Aurora, Colorado, United States
Florida Oncology Associates, Jacksonville, Florida, United States
Ocala Oncology Center, Ocala, Florida, United States
Iowa Oncology Associates, Cedar Rapids, Iowa, United States
Oncology/Hematology Associates of Kansas City, Kansas City, Missouri, United States
Piedmont Hem Onc Assoc, P.A., Winston-Salem, North Carolina, United States
Dayton Oncology/Hematology Consultants, Dayton, Ohio, United States
Willamette Valley Cancer Center, Eugene, Oregon, United States
Cancer Centers of the Carolinas, Greenville, South Carolina, United States
Southwest Regional Cancer Center, Austin, Texas, United States
Hematology Oncology Associates of South Texas, San Antonio, Texas, United States
Tyler Cancer Center, Tyler, Texas, United States
Oncology & Hematology Associates of Southwest Virginia, Roanoke, Virginia, United States
Cancer Care Northwest, Spokane, Washington, United States